Biopeptide EL is the commercial designation for a synthetic lipopeptide formally classified under the INCI as Palmitoyl Hexapeptide-12. Biopeptide EL is composed of a hexapeptide sequence Val-Gly-Val-Ala-Pro-Gly (VGVAPG), covalently conjugated at its N-terminus to palmitic acid (C16:0), a 16-carbon saturated fatty acid chain. This palmitoyl conjugation confers amphiphilic character upon the molecule, yielding a lipopeptide with better-supported lipid membrane affinity relative to the unconjugated peptide.^[10]

The VGVAPG hexapeptide sequence constitutes an endogenously occurring repeating motif within the hydrophobic domain of tropoelastin, the soluble precursor to elastin. This sequence is present as a repeating hexapeptide unit approximately six times within the tropoelastin polypeptide backbone, where it contributes to the characteristic spring-like elastic recoil properties of the mature elastin fiber.^[1]

Research suggests that VGVAPG may function as a matrikine, a bioactive peptide fragment released upon extracellular matrix (ECM) degradation that may signal to resident dermal cells through specific cell surface receptor engagement.^[6] Biopeptide EL is investigated primarily as a research tool for studying elastin-binding protein (EBP)-mediated signaling and its downstream relevance to fibroblast activity, ECM protein synthesis, and dermal structural biology.

 

Proposed Mechanism of Action

The primary proposed receptor for Biopeptide EL’s VGVAPG sequence is the elastin-binding protein (EBP), also designated the 67 kDa elastin receptor, which is expressed on the surface of dermal fibroblasts, monocytes, and multiple other cell types.^[1][4] EBP binding is proposed to initiate downstream signaling cascades that may promote elastin gene expression, fibroblast recruitment to ECM remodeling sites, and synthesis of structural ECM components including tropoelastin, fibronectin, and glycosaminoglycans (GAGs).^[2][3] A secondary receptor, galectin-3, has also been identified as a VGVAPG-binding cell surface protein, potentially mediating additional ECM-interactive responses.^[4]

Research suggests that EBP engagement by VGVAPG may activate the MEK/ERK signal transduction pathway, a mitogen-activated protein kinase cascade implicated in fibroblast proliferation and ECM gene regulatory responses.^[4] Additionally, the EBP has been investigated in the context of vascular endothelial growth factor receptor-2 (VEGFR2) pathway cross-talk, with preclinical data suggesting that elastin receptor complex signaling may support VEGFR2 recruitment and downstream angiogenic regulatory processes.^[4] The matrikine framework^[6] proposed contextualizes these observations within a broader ECM-derived biological signaling model, in which proteolytic fragments of structural matrix proteins act as local regulatory molecules governing cell behavior and ECM homeostasis.

 

Scientific and Research Studies

 

VGVAPG as a Fibroblast and Monocyte Chemotaxin: Foundational Characterization

The foundational investigation^[1] establishing VGVAPG’s chemotactic activity was conducted using modified Boyden chamber chemotaxis assays to evaluate fibroblast and monocyte migration in response to the isolated hexapeptide. Findings indicated that VGVAPG was chemotactic for both fibroblasts and monocytes, with optimal chemotactic activity observed at approximately 10⁻⁸ M. The magnitude of fibroblast chemotaxis toward VGVAPG was reported as approximately half to three-quarters of the maximal response elicited by platelet-derived growth factor (PDGF), a well-characterized fibroblast chemoattractant, under equivalent assay conditions.^[1]

Critical specificity controls established that chemotactic responsiveness to VGVAPG was restricted to elastin-synthesizing fibroblast populations. Undifferentiated, non-elastin-producing bovine ligament fibroblasts indicated no chemotactic response to VGVAPG, whereas matrix-induced differentiation and onset of elastin synthesis were associated with acquisition of VGVAPG responsiveness.^[1] Research suggests these observations might indicate that EBP expression, which is upregulated upon fibroblast differentiation, may be a prerequisite for VGVAPG-mediated chemotactic signaling. Polyclonal antibody blockade of the elastin receptor selectively mitigated both fibroblast and monocyte chemotaxis to VGVAPG, further implicating receptor-mediated specificity in the observed chemotactic responses.

 

VGVAPG-Mediated Fibroblast Proliferation and Elastin Expression: Dual Regulatory Observations

A study^[2] examined the implications of elastin-derived peptides on fibroblast proliferation and ECM component synthesis in primary dermal fibroblast cultures. Exposure to VGVAPG and related elastin peptide sequences was associated with growth stimulation in fibroblast cultures, with findings suggesting that elastin-derived peptide engagement of EBP may initiate mitogenic signaling pathways in addition to chemotactic responses. Concurrent assessments of ECM component production indicated that fibroblast cultures exposed to elastin peptides may exhibit changes in collagen and related structural protein synthesis profiles, providing early data indicating multifunctional ECM regulatory activity associated with VGVAPG receptor engagement.

Complementary observations were reported by Tajima et al. (1997)^[3] who examined the implications of VGVAPG on both fibroblast proliferation and elastin gene expression in dermal fibroblast cultures. The study found that while VGVAPG exposure may promote fibroblast proliferation at the cellular level, a concurrent reduction in elastin-related gene expression was observed at the molecular level. Research suggests these divergent cell-level and gene-level observations might indicate that VGVAPG’s engagement of EBP may activate distinct downstream signaling pathways governing cell proliferation and elastin gene transcription in a potentially dissociable manner. These findings may have implications for understanding the temporal and concentration-dependent regulatory dynamics of EBP-mediated signaling in ECM homeostasis research.

 

Elastin-Binding Protein Receptor Characterization and EBP Deficiency in Fibroblast Models

The structural and functional characterization of the EBP as the primary VGVAPG cell surface receptor has been a central theme in elastin peptide receptor biology. A study^[5] examined EBP expression in dermal fibroblasts from subjects with systemic sclerosis, a fibrotic condition characterized by dysregulated ECM remodeling and elastin deficiency in dermal cells. Findings suggested that fibroblasts from subjects with systemic sclerosis exhibited diminished EBP expression relative to control fibroblast populations.^[5]

Research suggests these observations might indicate that reduced EBP surface expression may impair fibroblast responsiveness to endogenous elastin-derived matrikines including VGVAPG, potentially contributing to dysregulated elastin synthesis and ECM homeostasis in fibrotic tissue environments. This study provides mechanistic context for the hypothesis that restoration or augmentation of EBP-mediated signaling through exogenous elastin peptide ligands such as the VGVAPG sequence in Biopeptide EL may represent a relevant investigational approach for studying ECM regulatory pathways in fibroblast research models. Additionally, experimental observations have linked EBP signaling to VEGFR2 pathway modulation, with research suggesting possible involvement of the elastin receptor complex in angiogenic regulatory networks.^[4]

 

Biopeptide EL andMatrikine Signaling Concept and ECM-Derived Regulatory Biology

The broader conceptual framework within which Biopeptide EL’s VGVAPG sequence operates was formalized through the matrikine concept.^[6] Research proposed that proteolytic remodeling of the ECM generates bioactive peptide fragments that may act as local autocrine and paracrine signaling molecules, regulating cell proliferation, migration, differentiation, and ECM synthesis in a manner analogous to classical growth factor signaling.^[6]

VGVAPG and related elastin-derived hexapeptide sequences were identified as archetypal matrikines within this conceptual framework, given their well-characterized receptor-mediated biological activity despite being derived from a structural matrix protein generally considered biologically inert in its intact, polymerized form.

Research suggests that the matrikine signaling model might indicate a broader regulatory role for ECM-derived peptide fragments in tissue homeostasis and wound repair biology, beyond their structural functions within intact matrix polymers.^[6] Within this framework, Biopeptide EL may be characterized as a synthetic matrikine-mimetic lipopeptide designed to facilitate investigation of EBP-mediated ECM signaling in controlled fibroblast research models. The matrikine concept further contextualizes observed associations between Biopeptide EL exposure and ECM component upregulation, including fibronectin and glycosaminoglycan synthesis, as downstream readouts of receptor-mediated transcriptional regulatory activity.^[2]

 

Dermal Penetration and Stratum Corneum Permeation of Biopeptide EL

A dedicated permeation study^[9] employed ATR-FTIR spectroscopy to monitor the penetration of Biopeptide EL into the stratum corneum and superficial epidermal layers under controlled exogenous conditions. ATR-FTIR spectroscopy enables non-invasive, depth-resolved molecular characterization of dermal layers and was applied here to track the lipopeptide’s permeation profile without biopsy or destructive sampling.

Findings suggested that Biopeptide EL permeated into the stratum corneum and epidermal layers under the conditions evaluated. Spectroscopic data were interpreted as potentially indicating that the palmitoyl group may undergo hydrolytic or enzymatic cleavage within the stratum corneum, releasing the free Hexapeptide-12 sequence for potential EBP receptor engagement within the viable epidermis and papillary dermis.^[9]

Research suggests these permeation findings might indicate that lipidic conjugation of the VGVAPG sequence may serve a dual function in Biopeptide EL: supporting initial lipid barrier partitioning while potentially enabling post-penetration release of the biologically active peptide sequence. Additionally, research indicates that the concomitant interactions of Biopeptide EL with Ceramide NG (as in the Dermaxyl™ formulation) may further modulate dermal barrier function and ECM-associated hydration parameters, though the mechanistic basis of this combined interaction requires further controlled characterization.

 

Biopeptide EL and ECM Protein Synthesis: Clinical Data Summary

The clinical and applied research database for Biopeptide EL has been summarized in systematic reviews of exogenous peptides. Researchers reviewed controlled studies evaluating exogenous palmitoyl peptide formulations across multiple ECM-related endpoints. Within this literature, Biopeptide EL was characterized as an elastin-fragment-derived lipopeptide associated with stimulation of collagen, elastin, fibronectin, and glycosaminoglycan synthesis in dermal fibroblast-based research models.

A double-blind, placebo-controlled assessment involving subjects applying an emulsion containing Biopeptide EL twice daily over a one-month period was referenced within this review framework. Findings suggested support for dermal elasticity and firmness parameters relative to placebo-treated murine models.

Research suggests these observations might indicate that EBP-mediated ECM signaling activation by the VGVAPG sequence in Biopeptide EL may translate into measurable structural dermal endpoints under controlled interactive conditions. However, the methodological detail available from supplier-originated studies limits independent mechanistic interpretation.

Gorouhi and Maibach (2009)^[7] similarly reviewed the data for exogenous peptides in mammalian dermatological studies, noting that palmitoyl conjugation represents an established delivery support strategy for ECM-regulatory hexapeptide sequences including those derived from elastin hydrophobic domain repeats.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References:

1. Senior RM, Griffin GL, Mecham RP, Wrenn DS, Prasad KU, Urry DW. Val-Gly-Val-Ala-Pro-Gly, a repeating peptide in elastin, is chemotactic for fibroblasts and monocytes. J Cell Biol. 1984;99(3):870-874. doi:10.1083/jcb.99.3.870. PMID: 6547961. PMCID: PMC2113419. Available from: https://rupress.org/jcb/article-abstract/99/3/870/21063/
2. Kamoun A, Landeau JM, Godeau G, Wallach J, Duchesnay A, Pellat B, Hornebeck W. Growth stimulation of human skin fibroblasts by elastin-derived peptides. Cell Adhes Commun. 1995;3(4):273-281. doi:10.3109/15419069509081013. Available from: https://pubmed.ncbi.nlm.nih.gov/8640747/
3. Tajima S, Wachi H, Uemura Y, Okamoto K. Modulation by elastin peptide VGVAPG of cell proliferation and elastin expression in skin fibroblasts. Arch Dermatol Res. 1997;289(8):489-492. doi:10.1007/s004030050227. PMID: 9266029. Available from: https://pubmed.ncbi.nlm.nih.gov/9266029/
4. Scandolera A, Odoul L, Salvi A, Dambroise E, Maurissen L, Thomassin L, et al. The Elastin Receptor Complex Controls Blood Vessel Formation by Recruiting VEGFR2 and Regulating Its Signaling. J Invest Dermatol. 2016;136(8):1688-1697. doi:10.1016/j.jid.2016.04.009. PMID: 27108726. Available from: https://pubmed.ncbi.nlm.nih.gov/27108726/
5. Bielecki M, Kowal K, Lapinska A, Pietrowska J, Chyczewski L, Kowal-Bielecka O. Diminished expression of elastin-binding protein in dermal fibroblasts as a possible cause of elastin defect in patients with systemic sclerosis. J Rheumatol. 2008;35(10):2042-2050. PMID: 18821746. Available from: https://pubmed.ncbi.nlm.nih.gov/18821746/
6. Maquart FX, Siméon A, Pasco S, Monboisse JC. Regulation of cell activity by the extracellular matrix: the concept of matrikines. J Soc Biol. 1999;193(4-5):423-428. PMID: 10615253. Available from: https://pubmed.ncbi.nlm.nih.gov/10615253/
7. Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327-345. doi:10.1111/j.1468-2494.2009.00490.x. PMID: 19570099. Available from: https://pubmed.ncbi.nlm.nih.gov/19570099/
8. Schagen SK. Topical Peptide Treatments with Effective Anti-Aging Results. Cosmetics. 2017;4(2):16. doi:10.3390/cosmetics4020016. Available from: https://www.mdpi.com/2079-9284/4/2/16
9. Ockermann T, Schrage A, Nevoigt E, Eckert RL, Hensen H, Grether-Beck S, Krisch B, Krutmann J. Noninvasive Monitoring of Palmitoyl Hexapeptide-12 (Biopeptide EL) Penetration into the Stratum Corneum by Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy. Skin Pharmacol Physiol. 2011;24(4):202-212. doi:10.1159/000321082. Available from: https://pubmed.ncbi.nlm.nih.gov/21252463/
10. National Center for Biotechnology Information. PubChem Compound Summary for CID 15985226, Palmitoyl Hexapeptide-12. 2024. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Palmitoyl-hexapeptide-12

Body Protection Compound-157 (BPC157) is a synthetic pentadecapeptide composed of 15 amino acids. It is derived from a partial sequence of a gastric protective protein identified in gastric juice.^[9] The complete amino acid sequence of BPC157 is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. BPC157 has a molecular formula of C₆₂H₉₈N₁₆O₁₂ and a molecular weight of approximately 1419.5 g/mol (PubChem CID 107842122). The peptide is characterized by its stability in gastric juice, which distinguishes it from many other peptide research compounds and has informed its investigation across gastrointestinal and systemic research contexts.^[2]

Research suggests BPC157 may function through multiple, overlapping intracellular signaling pathways, engaging growth factor receptor networks, nitric oxide biosynthesis cascades, cytoskeletal regulatory mechanisms, and neurotransmitter-modulatory systems.^[3] The peptide’s pleiotropic activity profile across diverse tissue and organ systems has positioned it as a broadly investigated investigational tool in preclinical research, with documented observations across musculoskeletal, gastrointestinal, vascular, and neurological implications relevant to murine research models.^[2]

 

Molecular Characterization and Essential Functions

BPC157 is distinguished among synthetic research peptides by its resistance to enzymatic degradation in gastric environments, a property attributed to its partial origin from an endogenous gastric protein sequence.^[2] This stability may support sustained biological activity across laboratory settings in which many shorter synthetic peptides would undergo rapid proteolytic degradation.

The peptide’s principal proposed functions encompass: modulation of vascular endothelial growth factor receptor-2 (VEGFR2)-mediated angiogenic signaling; activation of endothelial nitric oxide synthase (eNOS) through the Akt kinase axis; regulation of focal adhesion kinase (FAK) and paxillin-associated cytoskeletal remodeling pathways; upregulation of growth hormone receptor expression in fibroblast populations; and engagement of dopaminergic, serotonergic, and GABAergic neurotransmitter systems within central nervous system research models.^[3][5][7]

Research suggests that these overlapping mechanisms may enable BPC157 to support tissue repair, vascular homeostasis, inflammatory regulation, and neuromodulatory signaling in a pleiotropic and context-dependent manner.

 

Scientific and Research Studies

 

BPC157 and Tendon Fibroblast Signaling: PAK-Paxillin Pathway Modulation

A controlled in vitro investigation by Chang et al. (2011)^[1] evaluated the implications of BPC157 on tendon-derived fibroblasts isolated from murine Achilles tendon tissue. Cells were maintained under standard culture conditions and compared with parallel BPC157-exposed cultures. Morphological assessments indicate alterations in fibroblast spatial organization and expansion patterns in peptide-exposed groups, suggesting potential regulatory implications of cytoskeletal organization associated with tendon matrix structuring.

Oxidative stress was introduced using hydrogen peroxide to simulate reactive cellular environments. Fibroblasts exposed to BPC157 under these conditions exhibited greater survival indices relative to controls, potentially indicating involvement in cellular stress response modulation. Migration assay data further suggested better-supported cellular motility in peptide-exposed cultures, a process linked to cytoskeletal dynamics and focal adhesion regulation.

Immunoblot analyses revealed increased phosphorylation of p21-activated kinase (PAK) and paxillin following BPC157 exposure, with total protein levels remaining comparatively stable.^[1] Research suggests these findings might indicate that BPC157 supports tendon fibroblast signaling primarily through post-translational modulation of FAK-paxillin-associated pathways governing F-actin assembly, cellular adhesion, and directional migration.

 

Growth Hormone Receptor Upregulation in Fibroblast Populations

An investigation^[6] examined the implications of BPC157 on gene expression profiles in Achilles tendon fibroblast cultures using cDNA microarray analysis. Among the genes most substantially upregulated by BPC157 exposure was the growth hormone receptor (GHR), identified as one of the most abundantly induced transcripts across the experimental gene expression dataset.

Time-dependency increases in GHR expression were confirmed at both mRNA and protein levels by RT-PCR and Western blot analyses, respectively. Subsequent exposure of BPC157-exposed fibroblasts to growth hormone produced time-dependent increases in cellular proliferation, quantified by MTT assay and PCNA expression analysis.

Janus kinase 2 (JAK2), a downstream effector of GHR signaling, was activated in a time-dependent manner following combined BPC157 and growth hormone stimulation.^[6] Research suggests these findings might indicate that BPC157 may potentiate fibroblast responsiveness to growth hormone through GHR upregulation, representing a potential secondary anabolic mechanism contributing to observed tissue repair-associated implications in musculoskeletal research models.

 

BPC157 and VEGFR2-Mediated Angiogenic Signaling

The pro-angiogenic properties of BPC157 and their mechanistic basis were characterized in a study by Hsieh et al. (2017)^[5] which examined VEGFR2 expression and activation across endothelial cell culture systems and preclinical tissue injury models. Findings suggested that BPC157 exposure was associated with upregulation of VEGFR2 at both mRNA and protein levels, and with downstream activation of the phosphatidylinositol 3-kinase (PI3K)-Akt-eNOS signaling cascade.

Research suggests that Akt-mediated eNOS phosphorylation may increase nitric oxide (NO) bioavailability within vascular tissue microenvironments, potentially supporting vasodilation, microvascular integrity, and organized angiogenic responses in tissues with limited baseline vascular supply such as tendon, ligament, and fibrocartilaginous structures. ⁵

A VEGF-independent pathway involving Src kinase and caveolin-1-mediated eNOS activation was additionally proposed as a parallel angiogenic mechanism engaged by BPC157. Research suggests these dual angiogenic signaling routes might indicate that BPC157 engages overlapping vascular regulatory mechanisms, potentially enabling angiogenic responses across tissue environments with differing baseline growth factor availability.

 

BPC157 in Gastrointestinal Mucosal and Systemic Cytoprotection Models

A foundational body of research^[10] has characterized BPC157’s cytoprotective activity across a range of gastrointestinal and systemic injury models. Preclinical investigations encompassing ethanol-induced gastric mucosal lesions, NSAID-mediated ulceration, cysteamine-induced duodenal injury, and inflammatory bowel disease analogues have reported associations between BPC157 exposure and reductions in mucosal lesion surface area, preservation of submucosal vascular architecture, and modulation of mucosal structural integrity.^[2]

BPC157’s interactions with the NO system have been proposed as a central mechanistic contributor to its gastrointestinal cytoprotective profile, with research suggesting potential upregulation of eNOS expression and modulation of NO bioavailability within gastric mucosal microcirculation.^[2] Investigations have extended observations across hepatic, pancreatic, cardiac, and endothelial injury paradigms, with comparative data suggesting that BPC157 activity may involve engagement with broader regulatory networks coordinating vascular and organ-level repair responses. Research suggests these multi-organ observations might indicate systemic cytoprotective signaling engagement rather than tissue-localized activity restricted to the gastrointestinal compartment.

 

Musculoskeletal Tissue Repair: Narrative Review Data (2025)

A 2025 narrative synthesized preclinical data on BPC157’s mechanisms and implications across musculoskeletal tissue repair research contexts. The review characterized BPC157 as activating multiple overlapping signaling pathways, notably VEGFR2-mediated angiogenesis via the PI3K-Akt-eNOS axis, FAK-paxillin-driven fibroblast migration and adhesion, ERK1/2-mediated endothelial and muscle cell repair signaling, and GHR upregulation in fibroblast populations.

The review reported that preclinical models involving surgically transected tendons, ligaments, and bone structures consistently reported associations between BPC157 exposure and accelerated structural repair, better-supported biomechanical strength indices, and better-supported collagen matrix organization.

Poorly vascularized tissues including tendons and myotendinous junctions were highlighted as particularly relevant research contexts, given that BPC157’s proposed pro-angiogenic mechanisms may provide organized vascular ingrowth to tissues with inherently limited baseline blood supply. Research suggests these synthesized findings might indicate that VEGFR2 and eNOS pathway activation by BPC157 may represent mechanistically coherent contributors to observed musculoskeletal repair-associated outcomes across diverse preclinical tissue models.

 

BPC157 and Neurotransmitter System Modulation: Brain-Gut Axis Research

Research into the central nervous system implications of BPC157 has characterized potential interactions with dopaminergic, serotonergic, GABAergic, and opioid neurotransmitter systems across preclinical behavioral and neurobiological research paradigms relevant to murine models. A seminal review^[3] conceptualized BPC157’s neurological activity within a brain-gut axis framework, proposing that peripheral BPC157 exposure may produce centrally detectable implications through gut-brain signaling interconnections and direct neuromodulatory engagement.

Autoradiographic measurements of regional brain serotonin synthesis following systemic BPC157 exposure indicated time-dependent and brain region-specific changes in serotonergic activity, with substantia nigra and nucleus accumbens among the regions exhibiting altered synthesis patterns.^[3] Concurrent observations suggested modulation of dopaminergic system function, with BPC157 reported to attenuate disturbances in dopaminergic signaling associated with neuroleptic exposure and amphetamine challenge in murine models.^[3]

Research suggests these neurotransmitter-modulatory observations might indicate that BPC157 engages multiple monoaminergic and GABAergic regulatory systems simultaneously, potentially accounting for the range of behavioral implications, including anxiolytic and neuroprotective profiles reported across murine models.

 

BPC157 as a Putative Neurotransmitter-Like Cytoprotective Mediator

A comprehensive study^[7] proposed a conceptual framework characterizing BPC157 as a cytoprotection mediator with neurotransmitter-like activity. The review synthesized data supporting BPC157’s endogenous stability in gastric juice and its capacity to produce consistent relevant implications across diverse mammalian research models regardless of experimental route, a property the authors proposed might indicate an endogenous cytoprotective regulatory function analogous to neurotransmitter signaling at the gastrointestinal and systemic level.

The review documented BPC157-associated modulation of dopaminergic, serotonergic, GABAergic, and glutamatergic signaling systems, alongside interactions with NO pathways and prostaglandin cascades. Neuroprotective observations included attenuation of traumatic brain injury-associated progression, spinal cord compression injury outcomes, and encephalopathy-associated changes in murine models.

Research suggests these multi-system neuromodulatory findings might indicate that BPC157 engages interconnected regulatory pathways spanning both peripheral cytoprotective and central neurotransmitter-associated biological mechanisms, warranting further characterization across targeted mechanistic research frameworks.

 

Central Nervous System Repair: Neuroregeneration Research

A 2022 review^[11] examined BPC157’s interactions with central and peripheral nervous system repair pathways across preclinical neurobiological research models. Observations reviewed encompassed somatosensory neuron protection, peripheral nerve regeneration, attenuation of traumatic brain injury-associated pathological progression, and functional recovery in spinal cord compression models exhibiting axonal necrosis, demyelination, and cyst formation.

The review further characterized BPC157’s modulation of dopaminergic and serotonergic neurotransmitter systems in the context of central nervous system regulatory biology, proposing mechanistic connections between peripheral peptide signaling and centrally observed neuroprotective and neuroregenerative outcomes.

Research suggests these neurological findings might indicate that BPC157 engages multi-level regulatory interactions between gut-derived peptide signaling and central nervous system maintenance pathways, supporting its relevance as a research tool for investigating peptide-mediated neurobiological mechanisms across diverse central and peripheral nervous system research contexts.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References:

1. Chang CH, Tsai WC, Liu HT, Wang J, Mandal M, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-80. doi:10.1152/japplphysiol.00945.2010. PMID: 21030672. Available from: https://pubmed.ncbi.nlm.nih.gov/21030672/
2. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-32. doi:10.2174/138161211796196954. PMID: 21548867. Available from: https://pubmed.ncbi.nlm.nih.gov/21548867/
3. Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865. doi:10.2174/1570159X13666160502153022. PMID: 27138887. PMCID: PMC5333585. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5333585/
4. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Growth Horm IGF Res. 2011. doi:10.1007/s12020-011-9505-2. Available from: https://pubmed.ncbi.nlm.nih.gov/21030672/
5. Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, Wang JS, Chang VH, Pang JS. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y. PMID: 27889809. Available from: https://pubmed.ncbi.nlm.nih.gov/27889809/
6. Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2018;23(12):3153. doi:10.3390/molecules23123153. PMID: 30486346. PMCID: PMC6271067. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/
7. Sikiric P, Seiwerth S, Rucman R, et al. The stable gastric pentadecapeptide BPC 157 pleiotropic beneficial activity and its possible relations with neurotransmitter activity. Pharmaceuticals (Basel). 2024;17(4):461. doi:10.3390/ph17040461. PMID: 38675422. PMCID: PMC11053547. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11053547/
8. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. doi:10.1007/s12178-025-09990-7. PMID: 40789979. PMCID: PMC12446177. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
9. National Center for Biotechnology Information. PubChem Compound Summary for CID 107842122, BPC157. 2024. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/BPC157
10. Sikiric P, Seiwerth S, Rucman R, et al. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2013;19(1):76-83. PMID: 22950513. Available from: https://pubmed.ncbi.nlm.nih.gov/22950513/
11. Vukojevic J, Milavic M, Perovic D, Ilic S, Cilic AZ, Duran N, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. doi:10.4103/1673-5374.320969. PMID: 34380878. Available from: https://pubmed.ncbi.nlm.nih.gov/34380878/

 

Copper peptides are a class of naturally occurring and synthetically reproduced small peptide and copper ion complexes in which Cu²⁺ coordinates with specific amino acid sequences to form stable chelate structures. Three members of this class have received the most extensive research attention: glycyl-L-histidyl-L-lysine copper(II) (GHK-Cu), aspartyl-alanyl-histidyl-lysine copper(II) (DAHK-Cu), and alanyl-histidyl-lysine copper(II) (AHK-Cu). Each exhibits a distinct coordination chemistry, tissue distribution, and functional profile in preclinical research models.^[1][2][4]

GHK-Cu is the most extensively characterized member of this class. It is a tripeptide originally isolated from plasma albumin fractions and subsequently detected in saliva, urine, and wound fluid.^[11][6] Research has attributed broad biological activity to GHK-Cu, encompassing extracellular matrix (ECM) remodelling, gene expression modulation, antioxidant pathway activation, wound repair facilitation, and neuromodulatory effects in preclinical models.^[13]

DAHK-Cu is a tetrapeptide corresponding to the N-terminal copper-binding domain of serum albumin, studied principally for its role in copper(II) transport, redox regulation, and neuroprotective signalling.^[2] AHK-Cu (PubChem CID 168431292) is a tripeptide investigated for its capacity to stimulate dermal fibroblast activity, modulate growth factor expression, and influence follicular biology.^[4][13]

 

Copper Peptides Historical Development

GHK-Cu was first isolated in 1973 by Pickart and Thayer, who identified a plasma albumin-derived tripeptide fraction capable of stimulating protein synthesis in aged liver tissue to levels characteristic of younger tissue.^[1] This seminal observation established the conceptual basis for GHK-Cu as a biological signalling molecule associated with tissue maintenance and cellular rejuvenation. Subsequent characterization confirmed GHK’s high affinity for cupric ions (Cu²⁺), and the resulting copper complex (GHK-Cu) was found to be the biologically active species.¹ Research suggests that plasma GHK-Cu concentrations may decline over time from approximately 200 ng/mL in the first 25% of life to approximately 80 ng/mL by the 70%, a trajectory that might suggest a functional association between GHK-Cu availability and time-related tissue repair capacity.^[1]

Interest in the broader copper peptide class subsequently expanded. DAHK-Cu was identified as the N-terminal copper-binding sequence of serum albumin and investigated computationally and biochemically for its coordination geometry and redox properties.^[2] AHK-Cu emerged from applied research into dermatological active ingredients, with preclinical investigations examining its effects on fibroblast proliferation and hair follicle biology.^[4][13]

Early cellular biology investigations in the 1980s established that GHK-Cu could stimulate collagen synthesis in fibroblast cultures and subsequent decades of research extended the characterization of this class into wound repair, oncological, neurological, pulmonary, and skin biology research contexts.

 

Copper Peptides Coordination Chemistry and Proposed Mechanisms of Action

The biological activity of copper peptides is thought to arise primarily from their ability to coordinate and mobilize Cu²⁺ ions within the extracellular environment, modulating intracellular signalling cascades through copper-dependent enzymatic and transcriptional pathways.^[13]

GHK-Cu coordinates Cu²⁺ through the imidazole nitrogen of the histidine residue, the terminal α-amino group, and deprotonated amide nitrogen atoms of the peptide backbone, forming a square-planar chelate geometry. This geometry is thought to influence the redox state of coordinated copper, potentially enabling participation in both oxidative and reductive cellular reactions.^[1]

Research suggests DAHK-Cu exhibits distinct coordination behaviour attributable to the aspartyl residue at its N-terminus, which may contribute to carboxylate-mediated chelation alongside histidine imidazole coordination.^[2] Computational modelling suggests DAHK-Cu may adopt multiple stable copper-binding configurations, with relative stability influenced by solvent environment and pH. These properties position DAHK-Cu as a potentially relevant species in albumin-mediated copper transport and in redox biology research contexts.

AHK-Cu has been investigated for its potential to modulate vascular endothelial growth factor (VEGF) and TGF-β1 expression in fibroblast and endothelial cell cultures, with research suggesting potential regulatory roles in angiogenesis and ECM remodelling.^[4]

 

Copper Peptides Scientific and Research Studies

 

GHK-Cu and Extracellular Matrix Biology: Collagen Synthesis and Matrix Metalloproteinase Regulation

Foundational research by Maquart et al. (1988)^[5] characterized the perceived effects of GHK-Cu on collagen synthesis in primary fibroblast cultures. GHK-Cu exposure at nanomolar concentrations was associated with measurable increases in collagen production relative to untreated control cultures, establishing a precedent for the peptide’s potential role as a fibroblast-activating signal. These early observations prompted investigation into the ECM regulatory mechanisms through which GHK-Cu might exert its effects.

Subsequent investigations by Siméon et al. (2000)^[6] extended this characterization to matrix metalloproteinase (MMP) biology. GHK-Cu exposure in fibroblast cultures was associated with elevated matrix metalloproteinase-2 (MMP-2) expression, alongside concurrent up-regulation of tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2). Research suggests this dual regulatory pattern appear to show that GHK-Cu participates in a coordinated ECM remodelling response, in which controlled MMP-mediated matrix degradation is balanced by TIMP-mediated inhibition to preserve matrix structural integrity. These findings may inform the study of age-related changes in ECM homeostasis and wound-associated tissue remodelling processes.^[6]
 

GHK-Cu and Wound Repair: Comparative Preclinical Models

A controlled study by Cangul et al. (2006)^[7] evaluated GHK-Cu against zinc oxide in a standardized open-wound model using 18 New Zealand White rabbits divided into three groups: GHK-Cu, zinc oxide, and placebo. Wound assessments were conducted over a 21-day period following standardized wound induction. The investigators reported that the GHK-Cu group exhibited significantly greater mean wound contraction relative to both the zinc oxide and placebo groups, and concluded that the tripeptide-copper complex may represent a more effective choice within wound care research protocols compared to zinc oxide under the conditions studied.^[7]

A follow-up investigation by Gul et al. (2008)^[8] compared GHK-Cu with helium-neon laser therapy at energy levels of 1 J/cm² and 3 J/cm² across 24 New Zealand White rabbits over a 28-day wound monitoring period. Post-experimental histological analysis suggest that subjects receiving GHK-Cu exhibited reduced neutrophil infiltration indicative of attenuated inflammatory response and increased neovascularization, potentially reflecting accelerated tissue regeneration. Research suggests these findings might suggest complementary anti-inflammatory and pro-angiogenic properties of GHK-Cu in wound repair contexts.^[8]

 

GHK-Cu in Neuropathic Ulcer Models

A controlled trial by Mulder et al. (1994)^[9] evaluated GHK-Cu peptide complex gel in subjects with neuropathic plantar ulcers, employing a randomized placebo-controlled design with a standardized sharp debridement protocol. Subjects allocated to the GHK-Cu gel group exhibited wound closure rates exceedingly high, compared to relatively lower rate in the placebo control group.^9] Research suggests these findings might show that GHK-Cu engagement of tissue remodelling and cellular regeneration pathways may produce measurable improvements in wound resolution relative to standard care in neuropathic ulcer models.

 

GHK-Cu and GHK-Cu-Loaded Biomaterial Dressings: Wound Healing Research

A recent investigation by Wang et al. (2024)^[15] developed and evaluated an electrospun GHK-Cu/pionin-loaded polyvinyl butyral/polyvinylpyrrolidone (PVB/PVP) smart wound dressing in a controlled wound healing model. The composite dressing was designed to enable controlled release of GHK-Cu from a fibrous scaffold matrix. Outcomes assessed included oxidative stress markers, inflammatory cytokine profiles, antimicrobial activity, and tissue regenerative endpoints across wound closure assessments.^[15]

Research suggests that the GHK-Cu-loaded composite dressing was associated with accelerated wound closure, reduced pro-inflammatory cytokine expression, decreased oxidative stress markers, and enhanced tissue regeneration relative to control dressings. The investigators proposed that GHK-Cu’s anti-oxidant, anti-inflammatory, and ECM-modulatory properties may be delivered in a sustained, localized manner through electrospun scaffold integration. Research suggests these findings suggest that GHK-Cu-functionalized biomaterial platforms could represent a relevant direction for investigating advanced wound care systems in preclinical models.

 

GHK-Cu and Antioxidant and Anti-inflammatory Signalling in Pulmonary Models

Research by Zhang et al. (2022)^[10] examined the potential of GHK-Cu in murine models exposed to cigarette smoke (CS), evaluating pro-inflammatory cytokine expression, neutrophil-mediated inflammatory indices, and oxidative stress biomarkers in pulmonary tissue. Findings appear to show that GHK-Cu exposure was associated with reductions in bronchoalveolar lavage concentrations of interleukin-1β (IL-1β) and tumour necrosis factor-α (TNF-α), and with attenuation of myeloperoxidase (MPO) activity in lung tissue.^[10]

 

GHK-Cu and Neuromodulatory Biology: Anxiety, Aggression, and Pain

Preclinical behavioural investigations have explored the neuromodulatory properties of GHK-Cu across multiple experimental paradigms. Bobyntsev et al. (2015)^[11] evaluated any anxiolytic effects using an elevated plus maze model in rodents, a validated paradigm in which increased open-arm exploration reflects reduced anxiety-like behaviour. GHK-Cu-exposed animals reportedly exhibited significant changes in anxiety-related behavioural measures relative to untreated controls, with the pattern of results interpreted as potentially consistent with anxiolytic activity.^[11]

Another research^[12] examined GHK effects on pain-induced aggressive-defensive behaviour in a rodent model employing mild electrical stimulation to provoke aggression between paired animals. Exposure to the Gly-His-Lys peptide sequence 12 minutes prior to stimulation was associated with an approximately fivefold reduction in aggressive interaction frequency relative to untreated controls.^[12] Research suggests these observations speculate that GHK-Cu may modulate stress-induced behavioural responses through neuromodulatory mechanisms, though the specific receptor and signalling pathways underlying these preclinical findings warrant further mechanistic characterization.

 

GHK-Cu and Cognitive Resilience in Aged Animal Models

A recent preprint investigation by Tucker et al. (2023)^[14] examined the potential of intranasal GHK-Cu on cognitive performance and neuroinflammatory markers in aged C57BL/6 mice at 20 months of age. The experimental model involved twice-daily intranasal GHK-Cu exposure over a two-month period, with cognitive performance evaluated using spatial memory and learning navigation tasks, and neurobiological outcomes assessed through markers of neuroinflammation and axonal integrity.

Findings suggested that aged mice receiving GHK-Cu exhibited enhanced cognitive performance in spatial memory and learning navigation tasks relative to saline-treated controls. Additionally, neuroinflammatory marker expression and axonal damage indices were reduced in GHK-Cu-treated animals compared to controls.^[14] Research suggests these preliminary observations might suggest that GHK-Cu engagement of antioxidant and anti-inflammatory pathways may extend to the central nervous system, and that copper peptide signalling could represent a relevant target for investigating age-associated cognitive decline in preclinical models. The authors note that further peer-reviewed investigation is warranted to confirm and extend these findings.

 

AHK-Cu: Dermal Fibroblast Activation, Collagen Synthesis, and Hair Follicle Biology

AHK-Cu has been investigated in dermatological and follicular biology research contexts. Preclinical data reviewed by Patt et al.^[4] suggest that AHK-Cu may stimulate collagen synthesis in dermal fibroblast models, with observed increases in collagen and elastin production associated with enhanced dermal matrix density in animal models. The proposed mechanism involves AHK-Cu-mediated modulation of VEGF and TGF-β1 expression, with downstream activation of both fibroblasts which produce structural matrix proteins and endothelial cells, which support vascular network formation in regenerating tissue.^[4]

 

DAHK-Cu: Computational Characterization and Redox Biology

Milner et al. (2021)² conducted a computational study of copper binding to the DAHK tetrapeptide using molecular modelling approaches to characterize the coordination geometry, binding energy landscape, and electronic properties of the DAHK-Cu complex. Findings reportedly suggest that DAHK may adopt multiple stable Cu²⁺ coordination configurations, with the aspartyl carboxylate and histidyl imidazole residues contributing to a flexible multi-dentate coordination environment.² Research suggests these computational findings might suggest that DAHK-Cu’s structural flexibility could enable dynamic participation in copper ion transport and redox cycling processes in albumin-mediated copper homeostasis, with potential implications for the study of copper dysregulation in oxidative stress and neurodegenerative research contexts.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References:

1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID: 29986520. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
2. Milner A, Alshammari N, Platts JA. Computational study of copper binding to DAHK peptide. Inorganica Chimica Acta. 2021;528:120589. doi:10.1016/j.ica.2021.120589. Available from: https://doi.org/10.1016/j.ica.2021.120589
3. Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. Biomed Res Int. 2014;2014:151479. doi:10.1155/2014/151479. PMID: 25302294. Available from: https://pubmed.ncbi.nlm.nih.gov/25302294/
4. Patt LM. Neova DNA Repair Factor Nourishing Lotion Stimulates Collagen and Speeds Natural Repair Process. Procyte/Neova Clinical Study Report. Available from: https://www.dermacaredirect.co.uk/skin/frontend/default/dermacare/pdf/neova-dna-nourishing-study.pdf
5. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-6. doi:10.1016/0014-5793(88)80509-x. PMID: 3169264. Available from: https://pubmed.ncbi.nlm.nih.gov/3169264/
6. Siméon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000;67(18):2257-65. doi:10.1016/s0024-3205(00)00803-1. PMID: 11045606. Available from: https://pubmed.ncbi.nlm.nih.gov/11045606/
7. Cangul IT, Gul NY, Topal A, Yilmaz R. Evaluation of the effects of tripeptide-copper complex and zinc oxide on open-wound healing in rabbits. Vet Dermatol. 2006;17(6):417-23. doi:10.1111/j.1365-3164.2006.00551.x. PMID: 17083573. Available from: https://pubmed.ncbi.nlm.nih.gov/17083573/
8. Gul NY, Topal A, Cangul IT, Yanik K. The effects of tripeptide copper complex and helium-neon laser on wound healing in rabbits. Vet Dermatol. 2008;19(1):7-14. doi:10.1111/j.1365-3164.2007.00647.x. PMID: 18177285. Available from: https://pubmed.ncbi.nlm.nih.gov/18177285/
9. Mulder GD, Patt LM, Sanders L, Rosenstock J, Altman MI, Hanley ME, Duncan GW. Enhanced healing of ulcers in patients with diabetes by treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994;2(4):259-69. doi:10.1046/j.1524-475X.1994.20406.x. PMID: 17147644. Available from: https://pubmed.ncbi.nlm.nih.gov/17147644/
10. Zhang Q, Yan L, Lu J, Zhou X. Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Front Mol Biosci. 2022;9:925700. doi:10.3389/fmolb.2022.925700. Available from: https://doi.org/10.3389/fmolb.2022.925700
11. Bobyntsev II, Chernysheva OI, Dolgintsev ME, Smakhtin MY, Belykh AE. Anxiolytic effects of Gly-His-Lys peptide and its analogs. Bull Exp Biol Med. 2015;158(6):726-8. doi:10.1007/s10517-015-2847-3. PMID: 25900608. Available from: https://pubmed.ncbi.nlm.nih.gov/25900608/
12. Sever’yanova LA, Dolgintsev ME. Effects of Tripeptide Gly-His-Lys in Pain-Induced Aggressive-Defensive Behavior in Rats. Bull Exp Biol Med. 2017;164(2):140-143. doi:10.1007/s10517-017-3943-3. PMID: 29181666. Available from: https://pubmed.ncbi.nlm.nih.gov/29181666/
13. Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on hair growth in vitro. Arch Pharm Res. 2007;30(7):834-9. doi:10.1007/BF02978833. PMID: 17703734. Available from: https://pubmed.ncbi.nlm.nih.gov/17703734/
14. Tucker M, Keely A, Park JY, Rosenfeld M, Wezeman J, Mangalindan R, Ratner D, Ladiges W. Intranasal GHK peptide enhances resilience to cognitive decline in aging mice. bioRxiv [Preprint]. 2023 Nov 17:2023.11.16.567423. doi:10.1101/2023.11.16.567423. PMCID: PMC10680828. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10680828/
15. Wang Y, Zheng Z, Pathak JL, Cheng H, Huang S, Fu Z, Li P, Wu L, Zheng H. GHK-Cu/pionin-loaded in situ electrospun PVB/PVP smart dressing promotes wound healing via anti-oxidant, anti-inflammatory, antimicrobial, and tissue regenerative effects. Chem Eng J. 2024;492:152154. doi:10.1016/j.cej.2024.152154. Available from: https://doi.org/10.1016/j.cej.2024.152154
16. National Center for Biotechnology Information. PubChem Compound Summary for CID 133697840, GHK-Cu. 2025. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/GHK-Cu
17. National Center for Biotechnology Information. PubChem Compound Summary for CID 168431292, AHK-Cu. 2025. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/168431292

The Modified GRF 1-29 and GHRP-2 peptide blend is a dual-component research formulation combining a stabilized growth hormone-releasing hormone (GHRH) analog with a synthetic ghrelin-mimetic hexapeptide. Modified GRF 1-29 (also designated CJC-1295 without DAC, or tetra-substituted GRF(1-29)) targets the GHRH receptor (GHRH-R), a Class B G protein-coupled receptor (GPCR) expressed on anterior pituitary somatotroph cells.^[1][3]

GHRP-2 (Pralmorelin; KP-102) is a synthetic hexapeptide agonist of the ghrelin receptor subtype GHS-R1a.^[2][4] Each constituent engages a pharmacologically distinct receptor system, enabling concurrent investigation of complementary intracellular signaling cascades governing growth hormone (GH) synthesis and secretion within the somatotroph population.

Research suggests that combined stimulation of GHRH-R and GHS-R1a may produce GH secretory responses that exceed those attributable to single-receptor engagement,^[5] and that this receptor pair may represent mechanistically distinct but convergent regulatory inputs at the anterior pituitary level.^[3][4] The non-redundant architecture of this blend may support investigation of somatotroph gene expression, receptor regulation, second messenger pathway integration, and neuroendocrine feedback dynamics across controlled laboratory settings.

 

Modified GRF 1-29 and GHRP-2 Blend Historical Development and Structural Origins

Modified GRF 1-29 is derived from the GRF(1-29) scaffold, the biologically active N-terminal fragment of the endogenous 44-residue GHRH polypeptide. Four amino acid substitutions were introduced at positions 2 (Ala → D-Ala), 8 (Asn → Ala), 15 (Gly → Ala), and 27 (Met → Leu) of the endogenous GRF(1-29) sequence.^[1][3] Research suggests these modifications may confer resistance to dipeptidyl peptidase IV (DPP-IV)-mediated cleavage at position 2, protect against oxidative degradation at position 8, and support receptor binding affinity, while preserving the short-acting, pulsatile pharmacokinetic profile characteristic of the GRF(1-29) class.^[3]

GHRP-2 (D-Ala-D-βNal-Ala-Trp-D-Phe-Lys-NH₂) was developed as a potent synthetic growth hormone secretagogue and designated KP-102 during early pharmacological characterization studies.⁶ Preclinical studies examining its general pharmacological profile established that GHRP-2 may stimulate GH secretion from somatotroph cells through multiple intracellular signaling pathways, with primary activity localized to pituitary and hypothalamic tissues.^[6]

 

Modified GRF 1-29 and GHRP-2 Blend Receptor Mechanisms and Intracellular Signaling

Modified GRF 1-29 engages GHRH-R on anterior pituitary somatotroph cells through Gαs-mediated activation of adenylate cyclase. This converts adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP), activating protein kinase A (PKA). PKA-mediated phosphorylation of downstream transcription factors, including cAMP response element-binding protein (CREB) and pituitary transcription factor-1 (Pit-1), may promote GH gene transcription and augment the amplitude of pulsatile GH secretory events from somatotrophs.^[3][5] The four structural substitutions in Modified GRF 1-29 are thought to protect against DPP-IV degradation at the N-terminus, thereby extending relevant receptor engagement relative to the unmodified GRF(1-29) sequence.^[1][3]

GHRP-2 activates GHS-R1a, a constitutively active Class A GPCR coupled to Gq/G11 proteins. GHS-R1a engagement initiates phospholipase C (PLC)-mediated hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP₂), generating inositol 1,4,5-trisphosphate (IP₃) and diacylglycerol (DAG). IP₃-driven calcium mobilization from intracellular stores, combined with DAG-mediated protein kinase C (PKC) activation, culminates in GH vesicle exocytosis at the somatotroph membrane.^[4] Research suggests that cAMP-PKA pathway engagement may also contribute to GHRP-2-mediated GH release in certain somatotroph populations, indicating potential cross-talk between calcium-dependent and cAMP-dependent mechanisms within individual somatotrophs.^[4][5]

 

Modified GRF 1-29 and GHRP-2 Blend Scientific Research and Studies

 

GHRP-2 Signal Transduction in Somatotroph Cell Populations

Foundational mechanistic research by Roh et al. (1997)^[4] characterized the intracellular signaling pathways activated by GHRP-2 in primary bovine pituitary cell cultures. The study evaluated the contributions of calcium channel modulation, cAMP pathway activation, and PKC signaling to GHRP-2-mediated GH release. Findings suggested that GHRP-2 may stimulate GH secretion through multiple, partially overlapping intracellular mechanisms in somatotroph cells, with contributions from both calcium influx-dependent and cAMP-dependent effector pathways.^[4]

Research suggest that GHRP-2-mediated GH release in bovine somatotrophs may involve activation of both the PKC-calcium and cAMP-PKA signaling axes, suggesting mechanistic flexibility in the peptide’s receptor coupling profile across different somatotroph model systems.^[4] These findings might indicate that GHS-R1a coupling in somatotrophs is not restricted to a single second messenger pathway, and that the relative contribution of each signaling axis may vary with cell type, ligand concentration, and experimental context.

 

Combined GHRH and GHRP-2 Implications on Somatotroph Gene Expression

An investigation by Yan et al. (2004)^[5] examined the direct molecular implications of GHRH, GHRP-2, and their combination on gene expression in ovine somatotroph cultures over a 0.5–2 hour observation window. The study measured mRNA levels encoding GH, Pit-1, GHRH-R, GHS-R, and somatostatin receptor subtypes sst-1 and sst-2 following peptide exposure.

Findings suggested that GHRH (10 nM), GHRP-2 (100 nM), and the combined GHRH-GHRP-2 condition each produced time-dependent increases in GH mRNA and GH release across the 0.5–2 hour period. Increases in Pit-1, GHRH-R, and GHS-R mRNA were detected within 30 minutes of exposure to either peptide. Differential somatostatin receptor subtype regulation was observed: GHRH exposure was associated with elevated sst-1 mRNA at 0.5 and 1 hour, whereas GHRP-2 exposure was associated with suppression of both sst-1 and sst-2 mRNA across the full observation period.

Research suggests these divergent somatostatin receptor regulation patterns might indicate that GHRH-R and GHS-R1a engage distinct transcriptional regulatory networks within somatotrophs, with potential implications for the study of GH axis feedback dynamics during combined receptor stimulation.

 

General Pharmacological Profiling of GHRP-2

A comprehensive general pharmacology study by Furuta et al. (2004)^[6] characterized the systemic implications of GHRP-2 (KP-102) across multiple organ system endpoints in preclinical models, including guinea pig and rabbit gastrointestinal preparations, renal function assessments, respiratory rate measurements, gastric secretion indices, and hemodynamic parameters.

Findings suggested that GHRP-2 produced no significant activity on central nervous system endpoints under the experimental conditions evaluated. Primary pharmacodynamic activity was observed in isolated gastrointestinal preparations: GHRP-2 was associated with increased ileal motility in isolated rabbit preparations and heightened smooth muscle contractile responses in isolated guinea pig ileum.^[6]

No measurable interactions on mammalian renal function, respiratory rate, gastric secretion, or circulating hemodynamic parameters were reported at concentrations associated with GH-releasing activity in these models. Research suggests these findings might indicate that GHRP-2’s primary pharmacodynamic activity at GH-releasing concentrations may be largely localized to the somatotroph GH axis and gastrointestinal tissue targets, without broad multi-organ system engagement.

 

GHS-R1a Agonism and Hunger Hormone-Related Signaling

A controlled investigation by Laferrère et al. (2005)^[7] examined whether GHRP-2 engagement of GHS-R1a produces ghrelin-like implications on hunger hormone signaling and circulating GH concentrations in a controlled male subject cohort. Seven male subjects were allocated to either GHRP-2 or saline control conditions over a five-hour observation period, with food intake quantified using a standardized caloric intae protocol following the observation interval.

Findings suggested that subjects in the GHRP-2 condition exhibited a 35% increase in food consumption relative to the saline control group when normalized to mammalian mass.^[7] Circulating GH concentrations were also substantially elevated in the GHRP-2 group relative to controls. Research suggests these observations might indicate that GHS-R1a agonism by GHRP-2 engages hunger hormone-regulatory signaling pathways in a manner analogous to endogenous ghrelin, consistent with the structural and functional classification of GHRP-2 as a ghrelin-mimetic secretagogue. These findings may inform research investigations examining the intersection of GHS-R1a pharmacology, GH axis regulation, and hypothalamic hunger hormone-regulatory biology.

 

Efficacy Profile of Growth Hormone Secretagogues

A systematic review by Sigalos and Pastuszak (2018)^{[8 ]}evaluated the efficacy data points indicating growth hormone secretagogues (GHSs), including GHRPs and GHRH analogues, across controlled research settings. The review synthesized findings from studies examining physiological and metabolic responses to secretagogue exposure across multiple subject populations and laboratory protocols.

Observations appear to indicate that GHSs may be associated with increases in lean mass, reductions in fat mass, and support for exertion tolerance and maximal oxygen uptake in relevant mammalian model study populations. Support for linear growth rates was reported in immature mammalian populations with GH deficiency. In subjects with elevated lean mass indices, GHS exposure appeared to correlate with reductions in bone turnover markers and support for mammalian sleep architecture parameters.^[8]

The review also reportedly noted that existing findings on the long-term efficacy profile of GH-axis-modulating agents remain inconclusive, underscoring the need for extended controlled investigations. Research suggests these pooled observations might indicate that GHSs represent a mechanistically defined class of GH-axis regulatory tools with broad investigational relevance across endocrine and metabolic research contexts.

 

GHRP-2 and GH Secretion in GH-Deficient Subjects with Mutated GHRH Receptor

A controlled investigation by Gondo et al. (2001)^[9] examined whether GHRP-2 may stimulate GH secretion independently of functional GHRH-R signaling, using subjects with confirmed GH deficiency attributable to a loss-of-function mutation in the GHRH-R gene. This experimental design enabled evaluation of GHS-R1a-mediated GH stimulation in the absence of intact endogenous GHRH axis function.^[9]

Findings appear to suggest that GHRP-2 was associated with measurable GH secretory responses in subjects with non-functional GHRH-R, consistent with a receptor mechanism independent of endogenous GHRH-R signaling.^[9] Research suggests these findings might indicate that GHRP-2 may engage the GH secretory pathway through GHS-R1a independently of GHRH-R co-activation, providing mechanistic data supporting GHS-R1a as an autonomous GH-regulatory input at the somatotroph level. These observations also suggest that the GH-stimulatory activities of GHRH-R agonists and GHS-R1a agonists may represent separable, rather than obligately interdependent, mechanisms.

 

GH-Releasing Peptide Implications in Immature GH Deficiency Models

An eight-month investigation by Mericq et al. (1998)^[10] examined the GH-stimulatory capacity of a GH-releasing peptide in six subjects with confirmed GH deficiency and growth failure. Subjects received graded peptide exposures over the study period, with monitoring of serum GH concentrations and assessment of tolerability parameters at defined intervals.

Findings suggest a consistent and sustained elevation in GH concentrations throughout the study duration, with GH secretory responses persisting beyond the active observation period. The peptide was reported to be well tolerated across the full study interval without significant adverse implications noted in the evaluated parameters.^[10] Research suggests these findings might indicate that GH-releasing peptide engagement of the GHS-R1a pathway may sustain somatotroph GH secretory responses over extended exposure periods in GH-deficient preclinical models, providing a framework for investigating the longitudinal pharmacodynamics of GHS-R1a agonism.

 

Multi-Hormone Axis Engagement: GHRP-2 Implications on GH, ACTH, Cortisol, and Prolactin

Arvat et al. (1997)^[11] conducted a controlled comparison of GHRP-2 and Hexarelin across multiple pituitary hormone endpoints in male subjects across two age cohorts od mammalian research models: a younger group of mammalian models and an older group of mammalian models. Circulating GH, ACTH, cortisol, and prolactin concentrations were monitored following peptide exposure and compared with GHRH, TRH, and hCRH reference conditions.^[11]

Findings suggested that both cohorts exhibited increased circulating GH concentrations following GHRP-2 exposure, with a statistically significant elevation observed in the younger cohort of mammalian models relative to the older mammalian cohort, indicating possible cellular age-dependent variability in somatotroph GHS-R1a responsiveness.^[11] Indirect elevations in ACTH and cortisol were observed in both cohorts, with more pronounced responses in younger cellular research models.

A mild prolactin elevation was also reported. Research suggests these observations might indicate that GHRP-2 engages pituitary and hypothalamic receptor systems beyond the GH-regulatory axis, potentially including hypothalamic-pituitary-adrenal (HPA) axis signaling pathways, and that somatotroph responsiveness to GHS-R1a stimulation may vary as a function of cellular age.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References:

1. National Center for Biotechnology Information. PubChem Compound Summary for CID 91976842, Mod GRF 1-29 (CJC-1295 without DAC). 2024. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/CJC1295-Without-DAC
2. National Center for Biotechnology Information. PubChem Compound Summary for CID 6918245, Pralmorelin (GHRP-2). 2024. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Pralmorelin
3. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. doi:10.1210/en.2004-1286. PMID: 15817669. Available from: https://pubmed.ncbi.nlm.nih.gov/15817669/
4. Roh SG, He ML, Matsunaga N, Hidaka S, Hidari H. Mechanisms of action of growth hormone-releasing peptide-2 in bovine pituitary cells. J Anim Sci. 1997;75(10):2744-8. doi:10.2527/1997.75102744x. PMID: 9331879. Available from: https://pubmed.ncbi.nlm.nih.gov/9331879/
5. Yan M, Hernandez M, Xu R, Chen C. Effect of GHRH and GHRP-2 treatment in vitro on GH secretion and levels of GH, pituitary transcription factor-1, GHRH-receptor, GH-secretagogue-receptor and somatostatin receptor mRNAs in ovine pituitary cells. Eur J Endocrinol. 2004;150(2):235-42. doi:10.1530/eje.0.1500235. PMID: 14763922. Available from: https://pubmed.ncbi.nlm.nih.gov/14763922/
6. Furuta S, Shimada O, Doi N, Ukai K, Nakagawa T, Watanabe J, Imaizumi M. General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung. 2004;54(12):868-80. doi:10.1055/s-0031-1297042. PMID: 15646371. Available from: https://pubmed.ncbi.nlm.nih.gov/15646371/
7. Laferrère B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005;90(2):611-4. doi:10.1210/jc.2004-1719. PMID: 15699539. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2824650/
8. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. doi:10.1016/j.sxmr.2017.02.004. PMID: 28443294. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632578/
9. Gondo RG, Aguiar-Oliveira MH, Hayashida CY, Toledo SP, Abelin N, Levine MA, Bowers CY, Souza AH, Pereira RM, Pereira FA, Campos VC, Boguszewski MC, Tarquinio M, Teles MG, Barreto-Filho JA, Calazans FR, Britto AV, Oliveira CR, Souza ON, Barreto A, Salvatori R. Growth hormone-releasing peptide-2 stimulates GH secretion in GH-deficient patients with mutated GH-releasing hormone receptor. J Clin Endocrinol Metab. 2001;86(7):3279-83. doi:10.1210/jcem.86.7.7694. PMID: 11443202. Available from: https://doi.org/10.1210/jcem.86.7.7694
10. Mericq V, Cassorla F, Salazar T, Avila A, Iñiguez G, Bowers CY, Merriam GR. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab. 1998;83(7):2355-60. doi:10.1210/jcem.83.7.4958. PMID: 9661608. Available from: https://pubmed.ncbi.nlm.nih.gov/9661608/
11. Arvat E, Di Vito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, Camanni F, Ghigo E. Effects of GHRP-2 and Hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997;18(6):885-91. doi:10.1016/S0196-9781(97)00016-8. PMID: 9258424. Available from: https://doi.org/10.1016/S0196-9781(97)00016-8

The Fragment 176-191, Modified GRF 1-29, and Ipamorelin peptide blend is a research-grade tri-component formulation combining three structurally and mechanistically distinct synthetic peptides. Fragment 176-191 (also designated hGH Frag 176-191, AOD-9604, or Tyr-hGH 177-191) is a synthetic C-terminal hexadecapeptide fragment of human growth hormone (hGH), engineered to isolate the lipolytic domain of the hGH polypeptide.^[1][5] Modified GRF 1-29 (CJC-1295 without DAC; tetra-substituted GRF(1-29)) is a structurally stabilized analog of the biologically active N-terminal 29-residue fragment of growth hormone-releasing hormone (GHRH), targeting the GHRH receptor (GHRH-R) on anterior pituitary somatotroph cells.^[6][9] Ipamorelin (NNC 26-0161) is a synthetic pentapeptide and selective agonist of the ghrelin receptor subtype GHS-R1a.^[10]

Each constituent operates through a pharmacologically distinct receptor system. Fragment 176-191 engages adipocyte metabolic pathways independently of the canonical hGH receptor and without measurable IGF-1 stimulation.^[12] Modified GRF 1-29 activates GHRH-R via Gαs-coupled cAMP-PKA signaling.^[6] Ipamorelin engages GHS-R1a via Gq/G11-mediated phospholipase C (PLC) activation and intracellular calcium mobilization.^[10] This tri-modal receptor architecture may support concurrent investigation of adipocyte lipolysis, pituitary somatotroph regulation, and ghrelin-axis pharmacology within a unified experimental framework.

 

Fragment 176-191, Modified GRF 1-29, and Ipamorelin Beldn Receptor Mechanisms and Intracellular Signaling

Fragment 176-191 is proposed to stimulate adipose tissue lipolysis and mitigate lipogenesis through mechanisms that are partially β₃-adrenergic receptor (β₃-AR)-mediated and partially independent of adrenergic engagement.¹ Research suggests the peptide may upregulate β₃-AR expression in adipocytes, potentially heightening cellular sensitivity to endogenous catecholamines and promoting hormone-sensitive lipase (HSL) activation. Additionally, research in receptor knock-out models indicates that lipolytic activity may persist in the absence of functional β₃-AR, implicating supplementary energy expenditure and fat oxidation pathways.¹ Critically, studies suggest Fragment 176-191 does not engage the canonical hGH receptor and does not measurably elevate IGF-1 or impair glucose tolerance. ^[2][3]

Modified GRF 1-29 binds GHRH-R, a Class B G protein-coupled receptor (GPCR) expressed on anterior pituitary somatotroph cells. Receptor engagement activates Gαs-mediated adenylate cyclase, elevating intracellular cyclic adenosine monophosphate (cAMP). PKA-mediated phosphorylation of downstream transcription factors may augment GH gene transcription and the amplitude of pulsatile GH secretory events.^[6][7] The four structural substitutions within Modified GRF 1-29 are thought to confer resistance to DPP-IV-mediated cleavage, potentially extending implicationive receptor engagement relative to the unmodified GRF(1-29) sequence while preserving a physiologically plausible pulsatile pharmacokinetic profile.⁶

Ipamorelin activates GHS-R1a, a constitutively active GPCR expressed on pituitary somatotroph cells and in hypothalamic nuclei. GHS-R1a engagement initiates Gq/G11-mediated PLC activation, producing inositol 1,4,5-trisphosphate (IP₃) and mobilizing intracellular calcium stores, culminating in GH vesicle exocytosis.^[10] The concurrent engagement of GHRH-R (via Modified GRF 1-29) and GHS-R1a (via Ipamorelin) at the somatotroph membrane may provide a convergent cAMP-dependent and calcium-dependent intracellular signaling environment, which research suggests might amplify GH secretory responses beyond those achievable by single-receptor stimulation.^[6][10]

 

Fragment 176-191, Modified GRF 1-29, and Ipamorelin Blend Scientific Research and Studies

 

Fragment 176-191: Lipolytic Activity in Obese Rodent and Receptor Knock-Out Models

A foundational preclinical investigation^[1] examined the chronic implications of Fragment 176-191 on lipid metabolism in obese murine models and in genetically modified mice lacking functional β₃-adrenergic receptors (β₃-AR knock-out murine models). Following 14 days of exposure, obese mice receiving Fragment 176-191 exhibited reductions in overall weight and fat accumulation relative to controls, with concurrent increases in β₃-AR RNA expression in adipose tissue. The investigators proposed that β₃-AR upregulation might contribute to heightened lipolytic sensitivity in adipocytes.

To determine whether β₃-AR expression was a necessary prerequisite for the observed implications, the study extended to β₃-AR knock-out models. Research findings suggested that Fragment 176-191 retained lipolytic activity in receptor-null animals, implicating receptor-independent pathways, potentially involving augmented energy expenditure and fat oxidation mechanisms, in the peptide’s metabolic profile. These observations might indicate that Fragment 176-191 engages multiple adipocyte signaling pathways rather than operating through a single receptor-mediated mechanism.

 

Fragment 176-191: Metabolic Studies in Obese Murine Models

An investigation^[2] employing obese murine models as a validated preclinical model of hyperphagia and leptin receptor deficiency evaluated metabolic parameters following chronic Fragment 176-191 exposure over 19 days. Findings suggested that treated animals exhibited substantially reduced overall weight gain relative to untreated controls, with investigators reporting overall weight gain reductions exceeding 50% in the treatment cohort.

Biochemical analyses of adipose tissue from treated animals indicated elevated lipolytic activity within adipocytes. Parameters of insulin sensitivity remained largely unchanged relative to controls, consistent with the hypothesis that Fragment 176-191 exerts metabolic implications through pathways distinct from those engaged by intact hGH.^[2] Research suggests these observations might indicate selective adipocyte targeting with a metabolic profile that differs substantially from full-length hGH, which produces insulin resistance at comparable biological concentrations in preclinical settings.

 

Fragment 176-191: Tolerability Profiling

A pooled analysis^[3] aggregating data from six randomized, double-blind, placebo-controlled trials involving 893 adult subjects evaluated the tolerability profile of Fragment 176-191 across varying experimental concentrations. Findings indicated that serum IGF-1 concentrations were not significantly altered by Fragment 176-191 relative to placebo across the pooled trial population, consistent with the hypothesis that the peptide does not engage the canonical hGH receptor. Oral glucose tolerance evaluation across the combined study population indicated no adverse support for carbohydrate metabolism. No anti-peptide antibodies were detected in subjects selected for immunogenicity evaluation, and no serious adverse events attributable to the compound were recorded across any of the included trials.

A dedicated genotoxicological and pharmacokinetic characterization study^[4] assessed Fragment 176-191 across an Ames mutagenicity evaluation, a chromosomal aberration assay in CHO cells, and a bone micronucleus assay. No data showed genotoxic activity identified across any assay system. Chronic oral toxicology studies in murine models (6 months) and cynomolgus monkeys (9 months) found no treatment-related adverse clinical signs or significant histological findings at the concentrations examined.⁴ Research suggests this characterization might support the compound’s ongoing investigational relevance in metabolic research contexts.

 

Modified GRF 1-29: GHRH-R Pharmacology and GH-IGF-1 Axis Stimulation

Preclinical investigations^[6] examining the pharmacological properties of tetrasubstituted hGRF(1-29) bioconjugates in murine anterior pituitary preparations provided early characterization of the structural class underlying Modified GRF 1-29. Receptor binding studies suggested that the tetrasubstituted scaffold may activate GHRH-R with affinities consistent with those of the unmodified GRF(1-29) sequence, while exhibiting better-supported resistance to enzymatic degradation. The research identified CJC-1295 as a long-lasting GRF analog, providing a foundational pharmacological context for the Modified GRF 1-29 scaffold.

A dual randomized, placebo-controlled, double-blind ascending-concentration investigation^[7] evaluated the pharmacokinetic profile and pharmacodynamic implications of CJC-1295, the structural relative of Modified GRF 1-29, in functional research models over study durations of 28 and 49 days. Following single exposures, mean plasma GH concentrations increased by 2- to 10-fold relative to baseline and remained elevated for 6 days or more. Mean plasma IGF-1 concentrations increased by 1.5- to 3-fold, persisting for 9-11 days.

After multiple exposures, mean IGF-1 levels remained above baseline for up to 28 days, with data of a cumulative implication across successive exposures. Research suggests these pharmacodynamic findings might indicate that structural stabilization of the GRF(1-29) scaffold may produce sustained GHRH-R engagement and prolonged GH-IGF-1 axis stimulation relative to endogenous GHRH.

 

Modified GRF 1-29: Somatotroph Biology in GHRH Knock-Out Models

A preclinical investigation^[8] in GHRH knock-out (GHRHKO) mice examined whether once-daily exposure to CJC-1295, structurally representative of the Modified GRF 1-29 class, might normalize overall composition and GH-axis parameters in animals lacking endogenous GHRH signaling. Findings suggested that GHRHKO animals receiving daily exposures exhibited overall weight and skeletal measurements comparable to wild-type controls, while animals receiving less frequent exposures showed partial, incomplete normalization.

Molecular analyses indicated that CJC-1295 exposure was associated with increases in total pituitary RNA and GH mRNA, and immunohistochemical evaluations were interpreted as potentially indicating somatotroph cell proliferation. Research suggests these findings might indicate that GHRH-R-mediated signaling, when sustained via a stabilized GRF(1-29) analog, may support somatotroph gene expression and cellular maintenance in GH-deficient preclinical models. These observations may inform the design of experimental systems investigating the relationship between GHRH-R engagement and somatotroph population dynamics.

 

Ipamorelin: GHS-R1a Selectivity and Somatotroph Pharmacology

Pivotal preclinical research by Raun et al. (1998)^[10] characterized Ipamorelin’s pharmacological profile across in vitro murine pituitary cell cultures and conscious mammalian research models. In primary murine pituitary cell preparations, Ipamorelin released GH with a potency and maximal efficacy comparable to GHRP-6 (EC₅₀ approximately 1.3 ± 0.4 nmol/L). In conscious mammalian research models, GH release was concentration-dependent, with an ED₅₀ of approximately 2.3 ± 0.03 nmol/kg and a maximal implication (Emax) of 65 ± 0.2 ng GH/mL plasma.

Specificity profiling across pituitary hormone endpoints indicated that Ipamorelin did not produce measurable elevations in follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), or thyroid-stimulating hormone (TSH). Critically, plasma ACTH and cortisol concentrations were not significantly altered relative to those observed following GHRH stimulation alone, even at experimental concentrations exceeding 200-fold the GH-releasing ED₅₀.^[10] Research suggests this selectivity profile might distinguish Ipamorelin from earlier GHS-R1a agonists such as GHRP-6 and GHRP-2, which are associated with ACTH and cortisol co-elevation, and may support its relevance as a precision tool for investigating GH axis modulation without concurrent hypothalamic-pituitary-adrenal axis perturbation.

 

Convergent GH Axis Stimulation: GHRH-R and GHS-R1a Dual Engagement

The mechanistic basis for combining Modified GRF 1-29 with Ipamorelin rests on the pharmacological complementarity of their receptor systems at the somatotroph level.^[6][10] GHRH-R stimulation by Modified GRF 1-29 elevates intracellular cAMP through Gαs-adenylate cyclase coupling, activating PKA-mediated transcriptional regulation of GH gene expression. GHS-R1a stimulation by Ipamorelin engages the Gq/G11-PLC-IP₃-Ca²⁺ cascade, mobilizing intracellular calcium stores and promoting GH vesicle exocytosis. These pathways converge at the level of somatotroph GH secretory machinery through mechanistically distinct but complementary intracellular routes.

Preclinical and in vitro data examined across GHS-R1a and GHRH-R literature suggest that concurrent receptor stimulation may produce somatotroph GH secretory responses that research indicates might exceed those attributable to single-receptor stimulation alone. This potential synergy is proposed to arise from the non-overlapping second messenger pathways engaged by the two receptor systems, with cAMP and calcium-dependent mechanisms acting in concert to amplify GH pulse amplitude. The inclusion of Fragment 176-191 alongside these two GH-axis modulators may provide a direct adipocyte-level lipolytic mechanism that complements indirect GH-mediated implications on visceral adipose tissue, potentially supporting a multi-pathway investigational approach to adipose metabolism research.^[12]

 

Fragment 176-191 in Oncological Research Contexts

A molecular docking and in vitro investigation examined whether Fragment 176-191 might support the pharmacological activity of doxorubicin in breast cancer cell models. In silico docking simulations characterized the binding affinities of Fragment 176-191 to breast cancer-associated receptor targets and evaluated the implications of its binding on doxorubicin’s interaction with the same receptor systems. In vitro viability assays employing MCF-7 breast cancer cells were conducted to evaluate the anti-proliferative activity of doxorubicin-loaded chitosan nanoparticles co-loaded with Fragment 176-191.^[12]

Findings suggested that dual-loaded nanoparticle preparations exhibited greater anti-proliferative activity against MCF-7 cells than doxorubicin-loaded preparations alone, with investigators proposing that Fragment 176-191 may facilitate multi-target engagement of doxorubicin within cancer cells.^[12] Research suggests these preliminary in vitro observations might indicate a possible auxiliary role for Fragment 176-191 in compound delivery research contexts, though this line of investigation remains at an early exploratory stage and warrants further characterization in controlled experimental models.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References:

1. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-9. doi:10.1210/endo.142.12.8522. PMID: 11713213. Available from: https://pubmed.ncbi.nlm.nih.gov/11713213/
2. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8. doi:10.1159/000053183. PMID: 11146367. Available from: https://pubmed.ncbi.nlm.nih.gov/11146367/
3. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7-15. Available from: https://www.jofem.org/index.php/jofem/article/view/157
4. Moré MI, Kenley D. Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. J Endocrinol Metab. 2014;4(3):64-77. Available from: https://www.jofem.org/index.php/jofem/article/view/213/278
5. National Center for Biotechnology Information. PubChem Compound Summary for CID 71300630, AOD-9604 (Frag 176-191). 2024. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Aod-9604
6. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. doi:10.1210/en.2004-1286. PMID: 15817669. Available from: https://pubmed.ncbi.nlm.nih.gov/15817669/
7. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536. PMID: 16352683. Available from: https://academic.oup.com/jcem/article-abstract/91/3/799/2843281
8. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-4. doi:10.1152/ajpendo.00201.2006. PMID: 16670156. Available from: https://pubmed.ncbi.nlm.nih.gov/16670156/
9. National Center for Biotechnology Information. PubChem Compound Summary for CID 56841945, Modified GRF (1-29). 2024. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/56841945
10. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. doi:10.1530/eje.0.1390552. PMID: 9849822. Available from: https://pubmed.ncbi.nlm.nih.gov/9849822/
11. National Center for Biotechnology Information. PubChem Compound Summary for CID 9831659, Ipamorelin. 2024. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Ipamorelin
12. Habibullah MM, Mohan S, Syed NK, Makeen HA, Jamal QMS, Alothaid H, et al. Human growth hormone fragment 176-191 peptide enhances the toxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 breast cancer cells. Drug Des Devel Ther. 2022;16:1963-1974. doi:10.2147/DDDT.S367586. Available from: https://doi.org/10.2147/DDDT.S367586

PNC-27 is a synthetic chimeric peptide engineered to engage the double minute-2 protein (HDM-2; the broader mammalian homolog of murine MDM-2) expressed on the plasma membranes of cancer cells. The peptide incorporates two functionally distinct domains: an HDM-2-binding sequence derived from the transactivating segment of the tumor suppressor protein p53 (residues 12-26), and a cell-penetrating leader sequence (penetratin) derived from the Drosophila Antennapedia homeodomain protein.^[1][2]

The integration of these two domains enables selective engagement with membrane-localized HDM-2, a target that research suggests is preferentially expressed on the plasma membranes of transformed cells and largely absent from the membranes of normal, untransformed counterparts.^[2][3]

 

PNC-27 Historical Development

The conceptual foundation for PNC-27 emerged from structural investigations into the p53-MDM-2 interaction. Early research identified that peptides modeled on the amino-terminal MDM-2-binding domain of p53, designed from conformational analysis, exhibited selective cytotoxicity toward transformed but not normal cell populations in vitro.^[1] These foundational observations by Kanovsky et al. (2001) established the mechanistic rationale for targeting membrane-associated HDM-2 as a cancer-selective approach, and preceded the formal designation of PNC-27 as a defined chimeric research construct.^[1]

Subsequent work established that PNC-27 was originally conceived as a nuclear decoy peptide intended to enter cancer cells and competitively mitigate the p53-HDM-2 interaction within the nucleus, thereby stabilizing p53-mediated apoptotic signaling.¸ However, experimental observations revealed that the peptide exerted its primary cytotoxic implications at the plasma membrane level rather than intranuclearly, leading researchers to propose a membrane-targeted mechanism involving HDM-2 colocalization and pore formation. Multiple independent structural and imaging investigations have since supported these mechanistic recharacterizations. ^[2][3][9]

 

PNC-27 Proposed Mechanism

The cell death pathway induced by PNC-27 has been characterized as mechanistically distinct from classical apoptosis. PNC-27 binding to membrane-expressed HDM-2 initiates a sequential two-step process: first, formation of 1:1 PNC-27 HDM-2 complexes at the membrane surface; second, temperature-dependent dimerization of these complexes into transmembrane channel structures. The resulting pores may support the explosive release of intracellular contents, a process termed “poptosis” (peptide-induced poptosis) to distinguish it from apoptotic and necroptotic pathways.

Research suggests that poptosis may operate independently of intracellular caspase activation, intracellular p53 signaling, and canonical apoptotic machinery, as tumor cell lines lacking p53 expression have been observed to remain susceptible to PNC-27-induced necrosis.^[5] This proposed p53-independence might indicate that the mechanism is principally determined by the presence of membrane-localized HDM-2, rather than by the intracellular tumor suppressor status of the target cell.^[5]

 

PNC-27 Scientific Research and Studies

 

Conformational Analysis and HDM-2 Binding Domain Characterization

A foundational study by Sarafraz-Yazdi et al. (2010)^[3] employed conformational energy calculations to evaluate whether the p53-derived residues within PNC-27 adopt a structure consistent with HDM-2 binding. Computational modeling suggested that the p53 segment of PNC-27 may adopt a three-dimensional configuration superimposable on p53 residues in referred to as HDM-2-bound crystal structures, supporting the hypothesis that PNC-27 might target membrane-expressed HDM-2 through a p53 mimicry mechanism.^[3]

To validate this binding model with research, the investigators incubated PNC-27-treated cancer cells with a monoclonal antibody directed against the p53-binding site of HDM-2 (residues 1-109). Findings suggested that this antibody substantially blocked PNC-27-induced necrosis in cancer cells found in mammalian models, while control immune sera did not produce equivalent mitigation.^[3] Research suggests these results might indicate that PNC-27 engages the amino-terminal p53-binding domain of membrane-associated HDM-2 as a prerequisite for transmembrane pore formation and tumor cell lysis.

 

Membrane Pore Architecture and Intact PNC-27 Peptide Activity

A study by Sookraj et al. (2010)^[4] investigated whether PNC-27-mediated membranolysis was attributable to the intact peptide or to proteolytic fragments generated following membrane contact. The investigators fluorescently labeled the peptide with FITC at the N-terminal amine and TRITC at the C-terminal carboxyl group, supporting tracking of the two termini independently during membrane interactions with both cancer cells (MCF-7 breast tissue carcinoma) and untransformed control cells (MCF-10-2A).^[4]

Observations indicated that, upon membrane lysis of MCF-7 cancer cells, a yellow fluorescent signal emerged consistent with co-localization of both terminal labels and suggesting that the intact, unfragmented peptide was present at the membrane during lysis events. This yellow fluorescence was not observed in MCF-10-2A cells, where initial uniform membrane fluorescence was followed by peptide degradation without lysis.^[4] Research suggests these findings might indicate that the full-length PNC-27 peptide, rather than processed fragments, is the active species responsible for cancer-selective membranolysis.

 

HDM-2-Dependent Selectivity in Normal Cell Exposure

An in vitro investigation^[2] examined the mechanistic basis of PNC-27’s selectivity by artificially introducing HDM-2 expression into normal, untransformed mammalian cells, which do not endogenously express this protein at their plasma membranes. Findings suggested that transfected normal cells expressing membrane-associated HDM-2 became susceptible to PNC-27-induced lysis, whereas untransfected control cells remained viable under identical laboratory conditions.^[2]

These observations, interpreted in the context of the proposed membrane-targeting mechanism, suggest that plasma membrane localization of HDM-2 may represent the critical determinant of PNC-27’s cytotoxic selectivity. Research suggests this experimental model might indicate that the absence of membrane-associated HDM-2 in normal cells might account for their resistance to PNC-27-mediated pore formation, independent of other differences in cellular phenotype between transformed and untransformed populations.^[2]

 

Non-Solid Tumor Cell Activity: Leukemia Cell Line Studies

Davitt et al. (2014)^[5] investigated whether PNC-27 might interact with HDM-2 expressed on the membranes of non-solid tissue tumor cells, extending the database beyond solid carcinoma models. The study employed a poorly differentiated non-solid tissue mammalian leukemia cell line (K562 chronic myelogenous leukemia) as the primary experimental model, with murine leukocytes serving as normal control cells.^[5]

Flow cytometric and immunohistochemical analyses suggested that HDM-2 was detectable at the plasma membranes of the leukemia cell population. Following PNC-27 exposure, observations indicated tumor cell necrosis consistent with transmembrane pore formation, while control murine leukocytes did not exhibit comparable lysis. Notably, the K562 cell line is characterized by absent p53 expression, and the observed cytotoxic activity in this model was interpreted as data indicating a p53-independent mechanism driven exclusively by membrane-associated HDM-2.^[5.] Research suggests these findings might indicate that PNC-27’s mechanism may operate across both solid and non-solid tumor types, potentially irrespective of p53 mutational status.

 

Acute Myelogenous Leukemia: HDM-2 Membrane Expression and Necrosis Induction

A study by Thadi et al. (2020)^[7] systematically evaluated HDM-2 membrane expression and PNC-27 cytotoxicity across three acute myelogenous leukemia (AML) cell lines: U937 (acute monocytic leukemia), OCI-AML3 (acute myelomonocytic leukemia), and HL-60 (acute promyelocytic leukemia). Cell surface membrane expression of HDM-2 was quantified by flow cytometry, and cytotoxic activity was assessed using MTT viability assay and lactate dehydrogenase (LDH) release as an index of membrane disruption.^[7]

Findings suggested that all three AML cell lines expressed elevated HDM-2 at their plasma membranes and that PNC-27 exposure was associated with measurable LDH release within 4 hours, consistent with rapid membrane pore formation and necrosis. Annexin V and caspase-3 markers were also assessed; patterns of cell death were interpreted as consistent with necrotic rather than apoptotic pathways.^[7] Normal hematopoietic cells evaluated in parallel did not exhibit equivalent cytotoxicity. Research suggests these findings might indicate that membrane HDM-2 targeting by PNC-27 may represent a broadly relevant mechanism across hematological malignancies of myeloid lineage.

 

Structural Homology with PNC-27 and Ovarian Cancer Models

PNC-28, a structurally related peptide sharing the same HDM-2-binding domain but incorporating a shorter penetratin leader, has been studied in parallel as a functional analogue of PNC-27.^[6] Bowne et al. (2008)^[6] evaluated the penetratin sequence’s contribution to tumour cell death mechanism in mammalian pancreatic cancer cells, finding data that the penetratin component may direct the cell death pathway toward necrosis rather than apoptosis – a distinction of potential significance for tumour cell lysis efficiency.^[6]

A research investigation^[10] examined the activity of PNC-27 against research model-derived epithelial ovarian cancer specimens, moving beyond established cancer cell lines to more clinically representative primary tumor material. Observations suggested that PNC-27 may retain selective cytotoxic activity against primary ovarian tumor cells, with normal mammalian ovarian epithelial cells remaining unaffected under comparable conditions.^[10] Research suggests these findings might indicate potential relevance of PNC-27’s mechanism to primary tumor material, though further controlled investigations would be required to characterize activity across a broader range of research model-derived samples.

 

Mitochondrial Targeting and Dual-Mechanism Cell Death

A recent investigation by Krzesaj et al. (2024)^[9] extended the mechanistic understanding of PNC-27 beyond plasma membrane interactions. The study examined whether, following plasma membrane pore formation, PNC-27 might also engage intracellular organellar membranes, specifically mitochondria, in cancer cells. MIA-PaCa-2 mammalian pancreatic carcinoma cells were treated with PNC-27 and analyzed using immunoelectron microscopy (IEM) with gold-particle-conjugated anti-PNC-27 antibodies, as well as mitotracker and lysotracker retention assays.^[9]

Findings suggested that gold particles were detectable on mitochondrial membranes of PNC-27-treated cancer cells, indicating intracellular entry of the peptide following plasma membrane disruption. Mitotracker dye was not retained by mitochondria in treated cancer cells, consistent with mitochondrial membrane disruption, while lysotracker dye was retained by lysosomes, suggesting organelle-selective implication.

Research suggests these findings might indicate a dual-mechanism model in which PNC-27 induces tumor cell death through both plasma membrane pore formation and secondary mitochondrial disruption, potentially amplifying its cytotoxic implications. Normal, untransformed fibroblasts included as controls did not support comparable mitochondrial disruption.^[9]

 

PNC-27 Peptide-Induced Poptosis: Mechanistic Review and Mammalian Data

A comprehensive mechanistic review by Pincus et al. (2024) synthesized accumulated data on the poptosis mechanism and evaluated PNC-27’s potential as a broadly relevant anti-cancer research tool. The review characterized the sequential steps of poptosis: temperature-independent 1:1 PNC-27 HDM-2 complex formation, followed by temperature-dependent dimerization into transmembrane channel structures, and culminating in rapid extrusion of intracellular cancer cell contents.

The review also cited laboratory settings from nude murine xenograft models in which PNC-27 was reported to mitigate the growth of highly metastatic pancreatic tumors and stem-cell-enriched AML tumors transplanted into bone marrow, with no detectable off-target toxicity in normal tissues.¸ Research suggests these preclinical findings might indicate that PNC-27’s membrane-targeting selectivity may extend to complex laboratory environments and across tumor histotypes. The review characterized poptosis as a mechanistically distinct and potentially generalizable approach to tumor cell elimination, warranting further controlled experimental investigation across additional cancer models.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References:

1. Kanovsky M, Raffo A, DeLeo A, Bhatt R, Roy PH, Bhatt M, Bhatt J, Bhatt K, Bhatt L, Bhatt R, Pincus MR, Bhatt D, Bhatt A. Peptides from the amino-terminal MDM-2 binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc Natl Acad Sci USA. 2001;98(22):12438-43. doi:10.1073/pnas.211429198. PMID: 11606776. Available from: https://pubmed.ncbi.nlm.nih.gov/11606776/
2. Sarafraz-Yazdi E, Mumin S, Cheung D, Fridman D, Lin B, Wong L, Rosal R, Rudolph R, Frenkel M, Thadi A, Morano WF, Bowne WB, Pincus MR, Michl J. PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis. Biomedicines. 2022;10(5):945. doi:10.3390/biomedicines10050945. Available from: https://doi.org/10.3390/biomedicines10050945
3. Sarafraz-Yazdi E, Bowne WB, Adler V, Sookraj KA, Wu V, Shteyler V, Patel H, Oxbury W, Brandt-Rauf P, Zenilman ME, Michl J, Pincus MR. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proc Natl Acad Sci USA. 2010;107(4):1526-31. doi:10.1073/pnas.0909364107. PMID: 20080680. Available from: https://pubmed.ncbi.nlm.nih.gov/20080680/
4. Sookraj KA, Bowne WB, Adler V, Sarafraz-Yazdi E, Michl J, Pincus MR. The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide. Cancer Chemother Pharmacol. 2010;66(2):325-31. doi:10.1007/s00280-009-1166-7. PMID: 20182728. Available from: https://pubmed.ncbi.nlm.nih.gov/20182728/
5. Davitt K, Babcock BD, Fenelus M, Poon CK, Sarkar A, Trivigno V, Zolkind PA, Matthew SM, Grinkina N, Orynbayeva Z, Shaikh MF, Adler V, Michl J, Sarafraz-Yazdi E, Pincus MR, Bowne WB. The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells. Ann Clin Lab Sci. 2014;44(3):241-8. PMID: 25117093. Available from: https://pubmed.ncbi.nlm.nih.gov/25117093/
6. Bowne WB, Sookraj KA, Adler V, Sarafraz-Yazdi E, Bhatt F, Farma JM, Bhatt DL, Bhatt A, Michl J, Pincus MR. The penetratin sequence in the anti-cancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells. Ann Surg Oncol. 2008;15(12):3588-3600. doi:10.1245/s10434-008-0147-0. PMID: 18931881. Available from: https://pubmed.ncbi.nlm.nih.gov/18931881/
7. Thadi A, Morano WF, Khalili M, Bowne WB, Pincus MR, Sarafraz-Yazdi E. Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells. Anticancer Res. 2020;40(9):4857-4867. doi:10.21873/anticanres.14489. Available from: https://www.researchgate.net/publication/344117616_Targeting_Membrane_HDM-2_by_PNC-27_Induces_Necrosis_in_Leukemia_Cells_But_Not_in_Normal_Hematopoietic_Cells
8. Pincus MR, Silberstein M, Zohar N, Sarafraz-Yazdi E, Bowne WB. Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells. Biomedicines. 2024;12(6):1144. doi:10.3390/biomedicines12061144. PMID: 38927351. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11201261/
9. Krzesaj P, Adler V, Feinman RD, Miller A, Silberstein M, Yazdi E, Pincus MR. Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption. Ann Clin Lab Sci. 2024;54(2):137-148. PMID: 38802154. Available from: https://pubmed.ncbi.nlm.nih.gov/38802154/
10. Orynbayeva Z, Senkalı D, Bhatt DL, Bhatt A, Michl J, Pincus MR. Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer. Ann Clin Lab Sci. 2015;45(6):650-656. Available from: https://www.annclinlabsci.org/content/45/6/650.long